Vaccines developed by Aivita Biomedical use a patient's own blood to attack cancer and Covid-19. But the company also offers a consumer skin-care product that it plans to begin selling more widely.
AiVita is developing an immunotherapy for solid tumors, which may soon enter phase II clinical trials for ovarian cancer.
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.